WindMIL Therapeutics
PHILADELPHIA, PA · Founded 2015 · CIK 0001671352 · Biotech · Private
Reactivated marrow-infiltrating T-cell therapy for solid tumors
windmiltherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $45M
- 3 Form D · Feb 2021
- 68 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 28
- 0 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $32,525,358 | |
| Private capital raised | Form D · SEC | $2,334,814 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2348 | THYMMUNE THERAPEUTICS INC | — | — |
| 2349 | OmniTier, Inc. | — | $4.0M |
| 2350 | Memento Medicines | — | $38M |
| 2351 | WindMIL Therapeutics | — | $45M |
| 2352 | Illuminare Biotechnologies Inc | — | $6.0M |
| 2353 | Ostentus Therapeutics, Inc. | — | $1.8M |
| 2354 | Etheros Pharmaceuticals Corp. | — | $1.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Brian DoveyDirector
- Patrick FabbioExecutive Officer
- Allan FoxDirector
- Anna FrenchDirector
- Brian HalakDirector · Executive Officer
- Donald Hayden, Jr.Director · Executive Officer
- Mark McDadeDirector
- Daniel O'DonnellDirector
- Howard SouleDirector
Patents
- MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYapplication
- Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereofapplication
- MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYapplication
- Prostate Cancer Specific Marrow Infiltrating Lymphocytes and Uses Thereofapplication
- Use of Post-Transplant Cyclophosphamide Treated Allogenic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunityapplication
- Compositions and Methods for Modulating the Immune Systemapplication
- Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunityapplication
- Marrow Infiltrating Lymphocytes (mils) Expressing T Cell Receptors, Methods Of Manufacturing Same, And Method Of Using In Therapyapplication
- Products And Methods For Determining Antigens Useful In Cancer Immunotherapyapplication
- Glioblastoma Specific Marrow Infiltrating Lymphocytes And Uses Thereofapplication
- Head And Neck Cancer Specific Marrow Infiltrating Lymphocytes And Uses Thereofapplication
- Breast Cancer Specific Marrow Infiltrating Lymphocytes And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.